ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FOLD Amicus Therapeutics Inc

9.89
0.14 (1.44%)
May 22 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,203,687
Bid Price 9.00
Ask Price 15.80
News -
Day High 10.06

Low
9.02

52 Week Range

High
14.57

Day Low 9.69
Company Name Stock Ticker Symbol Market Type
Amicus Therapeutics Inc FOLD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.14 1.44% 9.89 00:00:01
Open Price Low Price High Price Close Price Prev Close
9.69 9.69 10.06 9.91 9.75
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
16,895 2,203,687 $ 9.89 $ 21,796,866 - 9.02 - 14.57
Last Trade Time Type Quantity Stock Price Currency
19:31:07 formt 100 $ 9.89 USD

Amicus Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.92B 295.38M - 399.36M -151.58M -0.51 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Amicus Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No FOLD Message Board. Create One! See More Posts on FOLD Message Board See More Message Board Posts

Historical FOLD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.4910.069.1259.542,505,4290.404.21%
1 Month10.8210.939.029.942,836,581-0.93-8.60%
3 Months13.9214.029.0211.233,022,833-4.03-28.95%
6 Months10.9214.579.0212.053,053,476-1.03-9.43%
1 Year11.9014.579.0212.112,746,988-2.01-16.89%
3 Years9.3114.575.9110.932,714,5160.586.23%
5 Years11.9225.395.9111.572,736,587-2.03-17.03%

Amicus Therapeutics Description

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Your Recent History

Delayed Upgrade Clock